China Biologic Products Holdings has concluded a final merger agreement with CBPO Holdings Limited. The transaction will total $4.76 billion or $120 per share of China Biologic Products Holding. The transaction is subject to shareholder approval and will be closed around the first half of 2021. If the merger is completed, the company will become private and its shares will no longer be traded on NASDAQ.
China Biologic Products Holdings has concluded a final merger agreement with CBPO Holdings Limited. The transaction will total $4.76 billion or $120 per share of China Biologic Products Holding. The transaction is subject to shareholder approval and will be closed around the first half of 2021. If the merger is completed, the company will become private and its shares will no longer be traded on NASDAQ. 
chinabiologic.investorroom.com
English (US) 